10:46 AM EST - Zomedica : Announced an assay agreement with IncellDx, a leading single cell cancer diagnostics company, to identify and enumerate circulating tumor cells (CTCs) from canine cancers using its BioINK Liquid Biopsy Reagent Platform. The investigational assay will incorporate biomarkers from Zomedica's canine cancer research programs with IncellDx's core BioINK reagents and novel cell cycle capabilities on CTCs. Zomedica
shares V.ZOM are trading unchanged at $2.00.
